MCID: CNT035
MIFTS: 65

Central Nervous System Disease

Categories: Neuronal diseases, Immune diseases

Aliases & Classifications for Central Nervous System Disease

MalaCards integrated aliases for Central Nervous System Disease:

Name: Central Nervous System Disease 12 14
Central Nervous System Diseases 41
Cns Diseases 51
Cns Disorder 69
Cns 44

Classifications:



Summaries for Central Nervous System Disease

Disease Ontology : 12 A nervous system disease that affects either the spinal cord (myelopathy) or brain (encephalopathy) of the central nervous system.

MalaCards based summary : Central Nervous System Disease, also known as central nervous system diseases, is related to neuromyelitis optica and meningoencephalitis, and has symptoms including hyperexplexia, hemiplegia and headache. An important gene associated with Central Nervous System Disease is MOG (Myelin Oligodendrocyte Glycoprotein), and among its related pathways/superpathways are Peptide ligand-binding receptors and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Propofol and Sevoflurane have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and testes, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 72 Central nervous system diseases, also known as central nervous system disorders, are a group of... more...

Related Diseases for Central Nervous System Disease

Diseases in the Nervous System Disease family:

Autoimmune Disease of Central Nervous System Congenital Nervous System Abnormality
Central Nervous System Disease

Diseases related to Central Nervous System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 180)
# Related Disease Score Top Affiliating Genes
1 neuromyelitis optica 32.5 GFAP MBP MOG
2 meningoencephalitis 32.4 APP BDNF MBP
3 nervous system disease 31.8 APP BACE1 BDNF CCR1 CXCR3 GC
4 panencephalitis, subacute sclerosing 31.0 MAPT MBP MOG
5 allergic encephalomyelitis 30.7 MBP MOG PLP1
6 multiple sclerosis 30.7 BDNF CCR1 CXCR3 GFAP IFNG IL1B
7 chlamydia 30.7 IFNG IL1B NOS2
8 mouth disease 30.6 IFNG IL1B TRPV1
9 pediatric cns embryonal cell carcinoma 11.9
10 sjogren-larsson-like ichthyosis without cns or eye involvement 11.8
11 pediatric cns choriocarcinoma 11.8
12 optic atrophy with demyelinating disease of cns 11.8
13 arthrogryposis multiplex congenita cns calcification 11.8
14 ectodermal dysplasia intellectual disability cns malformation 11.8
15 melanocytic lesions of cns 11.8
16 retinopathy anemia cns anomalies 11.8
17 neuronitis 11.2
18 meningitis 11.2
19 granulomatous amebic encephalitis 10.8
20 restless legs syndrome 10.8
21 intracranial abscess 10.8
22 epidural abscess 10.8
23 crohn's colitis 10.8 IFNG IL1B NOS2
24 eales disease 10.8 IFNG IL1B NOS2
25 cerebral hemorrhage 10.8 APP GFAP IL1B
26 corneal ulcer 10.8 CCR1 IL1B NGF
27 neuritis 10.8 IFNG IL1B MBP MOG
28 childhood disintegrative disease 10.8 APP BDNF MBP
29 leukoencephalopathy, hereditary diffuse, with spheroids 10.8 APP GFAP MAPT
30 allergic contact dermatitis 10.8 CXCR3 IFNG IL1B
31 lymphadenitis 10.8 CXCR3 IFNG IL1B
32 traumatic brain injury 10.8 BDNF GFAP MBP
33 burning mouth syndrome 10.8 IL1B NGF TRPV1
34 leukomalacia 10.8 GRM1 MBP NOS2
35 primary progressive multiple sclerosis 10.8 MBP MOG PLP1
36 neuroschistosomiasis 10.8 IFNG NGF
37 contact dermatitis 10.8 CXCR3 IFNG IL1B
38 autoinflammation, lipodystrophy, and dermatosis syndrome 10.8 IFNG IL1B NOS2
39 optic neuritis 10.8 MBP MOG PLP1
40 relapsing-remitting multiple sclerosis 10.8 BDNF IFNG MBP MOG
41 cerebral amyloid angiopathy, cst3-related 10.8 APP BACE1 MAPT
42 prion disease 10.8 APP IL1B MAPT
43 hypotrichosis 1 10.8 BACE1 GRM5 TRPV1
44 spinal cord injury 10.8 BDNF GFAP NOS2
45 somatoform disorder 10.8 IL1B NGF TRPV1
46 multiple system atrophy 1 10.8 GFAP MAPT MBP
47 inclusion body myositis 10.8 APP BACE1 CXCR3 MAPT
48 brain injury 10.8 BDNF GFAP MAPT MBP
49 bone inflammation disease 10.8 IFNG IL1B TRPV1
50 substance abuse 10.8 BDNF MOG PLP1

Graphical network of the top 20 diseases related to Central Nervous System Disease:



Diseases related to Central Nervous System Disease

Symptoms & Phenotypes for Central Nervous System Disease

UMLS symptoms related to Central Nervous System Disease:


hyperexplexia, hemiplegia, headache

MGI Mouse Phenotypes related to Central Nervous System Disease:

43 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.45 GRM1 GRM2 GRM5 HRH3 MAPT IFNG
2 homeostasis/metabolism MP:0005376 10.45 GRM1 GRM2 IL1B HRH3 MAPT IFNG
3 growth/size/body region MP:0005378 10.41 IFNG GRM1 IL1B GRM5 HRH3 MAPT
4 cellular MP:0005384 10.4 IFNG GRM1 GRM2 MAPT APP CCR1
5 immune system MP:0005387 10.29 IFNG IL1B HRH3 CCR1 APP CXCR3
6 cardiovascular system MP:0005385 10.28 IFNG IL1B HRH3 CCR1 APP CXCR3
7 mortality/aging MP:0010768 10.28 IFNG GRM1 IL1B GFAP BDNF CCR1
8 nervous system MP:0003631 10.25 GRM1 GRM2 IL1B GRM5 HRH3 MAPT
9 integument MP:0010771 10.2 IFNG GRM1 IL1B GRM5 MAPT APP
10 muscle MP:0005369 10.1 IFNG GRM1 APP BACE1 GFAP NGF
11 neoplasm MP:0002006 9.91 IFNG GRM1 IL1B CXCR3 MAPT NOS2
12 normal MP:0002873 9.81 IFNG GFAP BDNF APP CXCR3 BACE1
13 no phenotypic analysis MP:0003012 9.8 IFNG BDNF APP BACE1 NGF MAPT
14 renal/urinary system MP:0005367 9.5 IFNG GRM1 CCR1 CXCR3 MAPT NOS2
15 vision/eye MP:0005391 9.32 IFNG GRM1 GFAP BDNF MAPT NGF

Drugs & Therapeutics for Central Nervous System Disease

Drugs for Central Nervous System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1278)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 2078-54-8 4943
2
Sevoflurane Approved, Vet_approved Phase 4,Phase 2 28523-86-6 5206
3
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 83-43-2 6741
4
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 50-24-8 5755
5
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 84057-84-1 3878
6
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 99-66-1 3121
7
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
8
Levodopa Approved Phase 4,Phase 3,Phase 2,Phase 1 59-92-7 6047
9
Baclofen Approved Phase 4,Phase 2 1134-47-0 2284
10
Mannitol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 69-65-8 6251 453
11
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 59467-70-8 4192
12
Morphine Approved, Investigational Phase 4,Phase 2,Phase 3 57-27-2 5288826
13
Curcumin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 458-37-7 969516
14
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
15
Ketorolac Approved Phase 4,Phase 3,Phase 2,Phase 1 74103-06-3, 66635-83-4 3826
16
Metoclopramide Approved, Investigational Phase 4,Phase 3 364-62-5 4168
17
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-84-3 187
18
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 137-58-6 3676
19
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 1994-09-7, 94-09-7 2337
20
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 76631-46-4, 113775-47-6 5311068 56032 68602
21
Remifentanil Approved Phase 4,Phase 3 132875-61-7 60815
22
Sufentanil Approved, Investigational Phase 4,Phase 2 56030-54-7 41693
23
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 2 58-93-5 3639
24
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
25
Citalopram Approved Phase 4,Phase 2,Phase 3,Phase 1 59729-33-8 2771
26
Huperzine A Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 102518-79-6
27
Angiotensin II Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
28
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2 1397-89-3 5280965 14956
29
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 22916-47-8 4189
30
Lactulose Approved Phase 4,Phase 3,Phase 2 4618-18-2 11333
31
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 7440-66-6 32051 23994
32
Donepezil Approved Phase 4,Phase 3,Phase 2,Phase 1 120014-06-4 3152
33
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 19982-08-2 4054
34
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1 148553-50-8 5486971
35
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-78-2 2244
36
Rivaroxaban Approved Phase 4,Phase 2,Phase 3 366789-02-8
37
Rivastigmine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 123441-03-2 77991
38
Atenolol Approved Phase 4,Phase 3 29122-68-7 2249
39
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
40
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-23-7 657311 5754
41
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
42
Topiramate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 97240-79-4 5284627
43
Heparin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 9005-49-6 46507594 772
44 Nadroparin Approved, Investigational Phase 4 9041-08-1
45
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 1 129722-12-9 60795
46
Amantadine Approved Phase 4,Phase 2,Phase 3,Phase 1 768-94-5 2130
47
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
48
Galantamine Approved Phase 4,Phase 3,Phase 2,Phase 1 357-70-0 9651
49
Risperidone Approved, Investigational Phase 4,Phase 2,Phase 1 106266-06-2 5073
50
Acetazolamide Approved, Vet_approved Phase 4,Phase 2,Phase 3 59-66-5 1986

Interventional clinical trials:

(show top 50) (show all 10000)

# Name Status NCT ID Phase Drugs
1 Anesthesia Induction in Patients Undergoing Surgery for Cervical Myelopathy Unknown status NCT01052337 Phase 4 anaesthetics: sevofluorane
2 Immunotherapy in Intractable Cryptogenic Epilepsy Patients With Autoimmune Antibody Unknown status NCT02695797 Phase 4 Prednisolone
3 NIMIP: Non Invasive Measurement of the Intracranial Pressure Unknown status NCT01685450 Phase 4
4 The Impact of Reducing Overtreatment on Quality of Life in Children With Refractory Epilepsy Unknown status NCT00647322 Phase 4
5 Hormone Profiles in Adults With Newly Diagnosed Epilepsy Unknown status NCT00137709 Phase 4 Sodium valproate;Lamotrigine
6 Study to Improve the Treatment of Epilepsy (SITE) Unknown status NCT00133081 Phase 4 All registered antiepileptic drugs
7 Exoskeletons for Spinal Cord Injury: A Feasibility Study Unknown status NCT01943669 Phase 4
8 Eyegaze Systems for Spinal Cord Injury: A Feasibility Study Unknown status NCT01943656 Phase 4
9 Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study Unknown status NCT01361373 Phase 4 L- DOPA;placebo
10 Compare Tolerability of an Overnight Switch to Gradual Switch Between Two Different Forms of Depakote Unknown status NCT00312676 Phase 4
11 Functional Electrical Stimulation-Assisted Walking: Reduction of Secondary Complications Due to Spinal Cord Injury Unknown status NCT00201968 Phase 4
12 Does Oral Baclofen Improve Care and Comfort in Spastic Children in Nursing Homes? Unknown status NCT00752934 Phase 4 oral baclofen + placebo;placebo + oral baclofen
13 A Clinical Trial of the Effect of Midazolam on the Cerebral Metabolism and Inflammatory Response in Patients With Moderate and Severe Traumatic Brain Injury Unknown status NCT02071407 Phase 4 Midazolam;Placebo
14 A Comparison of Propofol Versus Midazolam to Sedate Critically Brain Injury; Measurement of Cytokine Response and Assessment of Function Unknown status NCT01712477 Phase 4 Intravenous sedation using propofol;Intravenous sedation with midazolam
15 Growth Hormone and Brain Functioning After Traumatic Brain Injury Unknown status NCT01699308 Phase 4 Genotropin (somatropin)
16 The CAPTAIN Trial: Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery Unknown status NCT01606111 Phase 4 Cerebrolysin;0.9% NaCl, saline
17 Effect of Rozerem on Sleep Among People With Traumatic Brain Injury Unknown status NCT01207050 Phase 4 Ramelteon
18 The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients Unknown status NCT02532023 Phase 4
19 Occipital Transcutaneous Stimulation in Chronic Migraine Unknown status NCT02307071 Phase 4
20 Preventive Treatment of Episodic and Chronic Migraine Unknown status NCT01319825 Phase 4 milnacipran
21 A Randomized Trial of Valproate Versus Ketorolac Versus Metoclopramide for Acute Migraine Unknown status NCT01267864 Phase 4 Metoclorpamide;Ketorolac;Valproate
22 American Migraine Prevention Study Unknown status NCT00363506 Phase 4
23 Botox for Neurogenic Detrusor Overactivity and the Prevention of Autonomic Dysreflexia Following SCI Unknown status NCT02298660 Phase 4 BOTOX
24 The Effect of Dexmedetomidine to Cognition of Geriatrics in Prolonged Surgery Unknown status NCT02123355 Phase 4 Induction of anesthesia;Sevoflurane, remifentanil ,vecuronium;Dexmedetomidine;Placebo
25 Effectiveness and Safety of Yiqitongluo Granule for Stroke Unknown status NCT02604654 Phase 4 Yiqitongluo granule
26 The Outcomes of Seamless ADL Training Between Occupational Therapist and Nurse in Stroke Patients Unknown status NCT02361307 Phase 4
27 4-point vs 4-roll Canne as Walking Aids After Stroke Unknown status NCT02279069 Phase 4
28 A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke Unknown status NCT02152280 Phase 4 Danhong Injection;Normal Saline
29 FINGER Robot Therapy Study Unknown status NCT02048826 Phase 4
30 Stratification of Blood Pressure Control Against Progress of Cerebral Small Vessel Diseases in Poststroke Patients Unknown status NCT01819441 Phase 4 Azelnidipine;Perindopril;hydrochlorothiazide
31 Creative Therapy to Affect Stroke Outcomes Unknown status NCT01455155 Phase 4
32 Effects on Clinical and Functional Outcome of Escitalopram in Adult Stroke Patients Unknown status NCT00967408 Phase 4 Escitalopram;Placebo
33 Functional Electrical Stimulation (FES) Assisted Walking: Enhancement of Walking Function After Stroke Unknown status NCT00552916 Phase 4
34 Early Warning and Optimization Strategy in Carotid Endarterectomy Unknown status NCT01210937 Phase 4
35 Consequence of Dexmedetomidine on Emergence Deliruim After Sevoflurane Anesthesia in Children With Cerebral Palsy Unknown status NCT02244515 Phase 4 dexmedetomidine
36 SAPPHIRE Worldwide: Stenting and Angioplasty With Protection in Patients At High-Risk for Endarterectomy Unknown status NCT00403078 Phase 4
37 Huperzine-A to Help With Mental Problems and the Inability to Care for Onself in Patients With Schizophrenia Unknown status NCT01012830 Phase 4 Huperzine A
38 Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST) Unknown status NCT00108706 Phase 4 Candesartan
39 The Impact of Botulinum Toxin Treatment in Quality of Life of Cervical Dystonia Patients Unknown status NCT01664013 Phase 4 Nuronox
40 Efficacy and Safety of DBS of the GPi in Patients With Primary Generalized and Segmental Dystonia Unknown status NCT00142259 Phase 4
41 Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis Unknown status NCT02686853 Phase 4 Liposomal amphotericin B
42 Trial Comparing Sedation for Endoscopy With Propofol Versus Midazolam in Cirrhotics Unknown status NCT01356121 Phase 4 Propofol;Midazolam
43 Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis Unknown status NCT01178372 Phase 4 Lactulose;Probiotics(VSL#3)
44 Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis Unknown status NCT01175538 Phase 4 Lactulose;Lactulose
45 Evaluation of the Efficacy and Safety of Levothyroxine in Brain Death Organ Donors: a Randomized Controled Trial Unknown status NCT02211053 Phase 4 Levothyroxine;placebo
46 Intensive Versus Nonintensive Insulin Therapy for Hyperglycemia After Traumatic Brain Injury Unknown status NCT02161055 Phase 4 Insulin
47 Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Unknown status NCT01954810 Phase 4
48 Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Minimal Encephalopathy Unknown status NCT00896831 Phase 4 L-ornithine-L-aspartate;placebo
49 Effect of Memantine Oral Pump on Language in Patients With Probable Alzheimer's Disease Unknown status NCT01849042 Phase 4 Ebixa;donepezil
50 Efficacy of Combined Oral L-Ornithine-L-Aspartate and Lactulose in Patients With Hepatic Encephalopathy Unknown status NCT00740142 Phase 4 L-ornithine-L-aspartate and lactulose;placebo and lactulose

Search NIH Clinical Center for Central Nervous System Disease

Cochrane evidence based reviews: central nervous system diseases

Genetic Tests for Central Nervous System Disease

Anatomical Context for Central Nervous System Disease

MalaCards organs/tissues related to Central Nervous System Disease:

38
Brain, Spinal Cord, Testes, Bone, Pituitary, Heart, Bone Marrow

Publications for Central Nervous System Disease

Articles related to Central Nervous System Disease:

(show top 50) (show all 312)
# Title Authors Year
1
Predicting the incidence and timing of central nervous system disease in metastatic melanoma: Implications for surveillance and preventative therapy. ( 29332716 )
2018
2
Is the Eye an Extension of the Brain in Central Nervous System Disease? ( 28609158 )
2017
3
Central nervous system disease in pediatric acute myeloid leukemia: A report from the Children's Oncology Group. ( 28453910 )
2017
4
Central nervous system disease in pediatric acute myeloid leukemia. ( 28853216 )
2017
5
Central Nervous System Disease in Antineutrophil Cytoplasmic Antibodies-Associated Vasculitis. ( 29061243 )
2017
6
Immunotherapeutics in Pediatric Autoimmune Central Nervous System Disease: Agents and Mechanisms. ( 29103429 )
2017
7
Inhibition of calcium dependent protein kinase 1 (CDPK1) by pyrazolopyrimidine analogs decreases establishment and reoccurrence of central nervous system disease by Toxoplasma gondii. ( 28933846 )
2017
8
Highly Expandable Human iPS Cell-Derived Neural Progenitor Cells (NPC) and Neurons for Central Nervous System Disease Modeling and High-Throughput Screening. ( 28075486 )
2017
9
Production of transgenic pigs using the<i>pGFAP-CreER<sup>T2</sup>;EGFP<sup>LoxP</sup></i>inducible system for central nervous system disease models. ( 29284207 )
2017
10
Occupational exposure to extremely low-frequency magnetic fields and risk for central nervous system disease: an update of a Danish cohort study among utility workers. ( 28429106 )
2017
11
Gpr124 is essential for blood-brain barrier integrity in central nervous system disease. ( 28288111 )
2017
12
Cerebrospinal fluid pleocytosis in infectious and noninfectious central nervous system disease: A retrospective cohort study. ( 28471963 )
2017
13
Metabolic Profiling of Central Nervous System Disease in Trypanosoma brucei rhodesiense infection. ( 28927234 )
2017
14
Wasp Venom Immunotherapy in a Patient With Immune-Mediated Inflammatory Central Nervous System Disease: Is it Safe? ( 28398199 )
2017
15
Central Nervous System Disease, Education, and Race Impact Radiation Refusal in Pediatric Cancer Patients. ( 28538508 )
2017
16
Editorial: Induction of Central Nervous System Disease by the Adaptive Immune Response. ( 29038655 )
2017
17
The effects of diet on the severity of central nervous system disease: One part of lab-to-lab variability. ( 27133811 )
2016
18
Clinical and Laboratory Findings That Differentiate Herpes Simplex Virus Central Nervous System Disease from Enteroviral Meningitis. ( 27563314 )
2016
19
Raccoon Roundworm Infection Associated with Central Nervous System Disease and Ocular Disease - Six States, 2013-2015. ( 27608169 )
2016
20
Molecular Analysis of Central Nervous System Disease Spectrum in Childhood Acute Lymphoblastic Leukemia. ( 26997880 )
2016
21
Central nervous system disease in childhood acute lymphoblastic leukaemia- a review. ( 26990196 )
2016
22
Clinical, electrophysiological, and biochemical markers of peripheral and central nervous system disease in canine globoid cell leukodystrophy (Krabbe'sA disease). ( 27638585 )
2016
23
Fatal Central Nervous System Disease Following First Infliximab Infusion in a Child With Inflammatory Bowel Disease. ( 26831951 )
2016
24
AMP-Activated Protein Kinase Suppresses Autoimmune Central Nervous System Disease by Regulating M1-Type Macrophage-Th17 Axis. ( 27354217 )
2016
25
Hodgkin Lymphoma With Central Nervous System Disease at Primary Presentation. ( 26814676 )
2016
26
Delivery of an adeno-associated virus vector into CSF attenuates central nervous system disease in mucopolysaccharidosis type II mice. ( 27510804 )
2016
27
Glial biomarkers in human central nervous system disease. ( 27228454 )
2016
28
Central nervous system disease and genital disease in harbor porpoises (Phocoena phocoena) are associated with different herpesviruses. ( 26861818 )
2016
29
Evaluation of AAV-mediated Gene Therapy for Central Nervous System Disease in Canine Mucopolysaccharidosis VII. ( 26447927 )
2015
30
Interaction between Tat and Drugs of Abuse during HIV-1 Infection and Central Nervous System Disease. ( 26793168 )
2015
31
Intranasal delivery of stem cells as therapy for central nervous system disease. ( 25645932 )
2015
32
Targeted Temperature Management in Pediatric Central Nervous System Disease. ( 26042193 )
2015
33
Macaque species susceptibility to simian immunodeficiency virus: increased incidence of SIV central nervous system disease in pigtailed macaques versus rhesus macaques. ( 25672885 )
2015
34
Flow cytometry for detection of central nervous system disease in acute myeloid leukemia. ( 25641427 )
2015
35
Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here? ( 26314739 )
2015
36
Widespread correction of central nervous system disease after intracranial gene therapy in a feline model of Sandhoff disease. ( 25474439 )
2015
37
Recurrent neonatal herpes simplex virus infection with central nervous system disease after completion of a 6-month course of suppressive therapy: Case report. ( 26390826 )
2015
38
Diagnostic value of aquaporin 4 antibody in assessing idiopathic inflammatory demyelinating central nervous system diseases in Egyptian patients. ( 25677878 )
2015
39
Neonatal Herpes Simplex Virus Type-1 Central Nervous System Disease with Acute Retinal Necrosis. ( 24378951 )
2014
40
Coxsackievirus-induced acute neonatal central nervous system disease model. ( 24696707 )
2014
41
ELR(+) chemokine signaling in host defense and disease in a viral model of central nervous system disease. ( 24987333 )
2014
42
Current developments in understanding of West Nile virus central nervous system disease. ( 24722324 )
2014
43
A coumarin-based fluorescent probe as a central nervous system disease biomarker. ( 25390405 )
2014
44
Distinct systemic and central nervous system disease patterns in enterovirus and parechovirus infected children. ( 24662038 )
2014
45
RNA-sequencing reveals oligodendrocyte and neuronal transcripts in microglia relevant to central nervous system disease. ( 25258010 )
2014
46
Epstein-Barr virus (EBV) load in cerebrospinal fluid and peripheral blood of patients with EBV-associated central nervous system diseases after allogeneic hematopoietic stem cell transplantation. ( 23692640 )
2013
47
HIV-Associated Central Nervous System Disease in Patients Admitted at the Douala General Hospital between 2004 and 2009: A Retrospective Study. ( 23533732 )
2013
48
RON receptor tyrosine kinase, a negative regulator of inflammation, is decreased during simian immunodeficiency virus-associated central nervous system disease. ( 24043899 )
2013
49
Detection and characterization of a divergent avian reovirus strain from a broiler chicken with central nervous system disease. ( 23771766 )
2013
50
The role of AEG-1/MTDH/LYRIC in the pathogenesis of central nervous system disease. ( 23889991 )
2013

Variations for Central Nervous System Disease

Expression for Central Nervous System Disease

Search GEO for disease gene expression data for Central Nervous System Disease.

Pathways for Central Nervous System Disease

Pathways related to Central Nervous System Disease according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.45 APP CCR1 CXCR3 GRM1 GRM2 GRM5
2 11.95 BDNF IL1B NGF PLP1
3 11.81 APP BACE1 GFAP GRM1 GRM2 GRM5
4 11.73 IFNG IL1B NOS2
5 11.67 IFNG IL1B NOS2
6
Show member pathways
11.64 APP BDNF NGF
7 11.62 CXCR3 IFNG IL1B
8
Show member pathways
11.52 APP BDNF NGF
9 11.51 BDNF GFAP IFNG IL1B MBP NOS2
10
Show member pathways
11.47 IFNG IL1B NOS2
11 11.46 BDNF GFAP MOG NGF
12 11.39 APP BACE1 GRM5
13 11.37 APP BACE1 MAPT
14 11.26 IFNG IL1B NOS2
15 11.2 APP BACE1 MAPT
16 11.07 IFNG IL1B NOS2
17 10.71 BDNF GRM1
18 10.54 GRM1 GRM2 GRM5
19 10.41 MBP PLP1

GO Terms for Central Nervous System Disease

Cellular components related to Central Nervous System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.97 APP BACE1 CCR1 CXCR3 GRM1 GRM2
2 presynaptic membrane GO:0042734 9.43 GRM1 GRM2 GRM5
3 neuron projection GO:0043005 9.35 APP GRM1 GRM2 GRM5 TRPV1
4 astrocyte projection GO:0097449 9.32 APP GFAP
5 integral component of plasma membrane GO:0005887 9.28 APP BACE1 CCR1 CXCR3 GRM1 GRM2

Biological processes related to Central Nervous System Disease according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 regulation of receptor activity GO:0010469 9.98 BDNF IFNG IL1B MAPT NGF
2 inflammatory response GO:0006954 9.92 CCR1 CXCR3 IL1B PLP1 TRPV1
3 cell surface receptor signaling pathway GO:0007166 9.91 CCR1 CXCR3 IFNG TRPV1
4 positive regulation of gene expression GO:0010628 9.91 APP IFNG IL1B NGF PLP1
5 locomotory behavior GO:0007626 9.77 APP GRM1 GRM5
6 regulation of insulin secretion GO:0050796 9.74 IFNG IL1B NOS2
7 positive regulation of nitric oxide biosynthetic process GO:0045429 9.65 IFNG IL1B TRPV1
8 chemical synaptic transmission GO:0007268 9.65 GRM1 GRM2 GRM5 MBP PLP1
9 synapse organization GO:0050808 9.63 APP GRM5 MAPT
10 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.62 IFNG IL1B
11 microglial cell activation GO:0001774 9.62 MAPT TRPV1
12 axon development GO:0061564 9.61 GFAP PLP1
13 amyloid fibril formation GO:1990000 9.58 APP MAPT
14 astrocyte activation GO:0048143 9.56 APP MAPT
15 axon ensheathment GO:0008366 9.55 MBP PLP1
16 negative regulation of gene expression GO:0010629 9.55 APP CCR1 IFNG MAPT NOS2
17 modulation of age-related behavioral decline GO:0090647 9.54 APP GRM5
18 regulation of synaptic transmission, glutamatergic GO:0051966 9.5 GRM1 GRM2 GRM5
19 fever generation GO:0001660 9.49 IL1B TRPV1
20 positive regulation of killing of cells of other organism GO:0051712 9.43 IFNG NOS2
21 regulation of postsynaptic cytosolic calcium ion concentration GO:0099566 9.4 GRM1 GRM5
22 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.37 IFNG IL1B
23 G-protein coupled glutamate receptor signaling pathway GO:0007216 9.13 GRM1 GRM2 GRM5
24 adenylate cyclase-inhibiting G-protein coupled glutamate receptor signaling pathway GO:0007196 8.8 GRM1 GRM2 GRM5
25 G-protein coupled receptor signaling pathway GO:0007186 10.14 APP CCR1 CXCR3 GRM1 GRM2 GRM5

Molecular functions related to Central Nervous System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor activity GO:0004930 9.8 CCR1 CXCR3 GRM1 GRM2 GRM5 HRH3
2 signal transducer activity GO:0004871 9.43 CCR1 CXCR3 GRM1 GRM2 GRM5 HRH3
3 structural constituent of myelin sheath GO:0019911 9.26 MBP PLP1
4 neurotransmitter receptor activity involved in regulation of postsynaptic cytosolic calcium ion concentration GO:0099583 9.16 GRM1 GRM5
5 glutamate receptor activity GO:0008066 8.8 GRM1 GRM2 GRM5

Sources for Central Nervous System Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....